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Abstract
Translational and evidence based medicine can take advantage of biotechnology advances that offer a fast
growing variety of high-throughput data for screening molecular activities of genomic, transcriptional, post-
transcriptional and translational observations. The clinical information hidden in these data can be clarified with
clinical bioinformatics approaches. We have recently proposed a method to analyze different layers of high-
throughput (omic) data to preserve the emergent properties that appear in the cellular system when all molecular
levels are interacting. We show here that this method applied to brain cancer data can uncover properties (i.e.
molecules related to protective versus risky features in different types of brain cancers) that have been
independently validated as survival markers, with potential important application in clinical practice.
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1 Background
We have recently presented in [1] an approach to iden-
tify the so called emergent properties of a biological sys-
tem, i.e. properties that arise from the interaction of
portions of a system. In particular, this method is based
on the integration of translational (microarrays for
mRNA gene expression) and post-translational (RT-PCR
of miRNAs) data and applied to observations related to
human brain tumors published in [2]. Emergent proper-
ties are a well known concept in Systems Theory and
are now becoming more common in Systems Biology
[3-6]. In general, the concept of emergent property
relates to the fact that a system studied in its entirety
shows features that cannot be captured when the system
is observed through its (simplified) subsystems (Reduc-
tionist approach). Applied to molecular biology, this cor-
responds to the observation that separate analyses of
different aspects of a system (e.g., transcriptional and/or
post-transcriptional mechanisms) lead to results that
may not be concordant with analyses of the system as a
whole. This may be due to underestimating or overlook-
ing interactions among miRNAs and mRNAs. The iden-
tification of emergent properties can be done through
the use of latent variables in multivariate statistics (in
particular via the use of Factor Analysis, FA, [7]). Latent
variables are so-called hidden variables which are not
evident in the original observed data, because they
emerge from consideration of the covariance patterns
when a large number of relevant variables are analyzed
simultaneously.
Taking advantage of the parallelism existing between
biological systems’ emergent properties and latent vari-
ables, we have used the ability of latent variables to
describe emergent properties, by applying multivariate
analysis simultaneously to different parts of a biological
system, and notably to transcriptional and post-transcrip-
tional data. In practice, each latent variable (i.e. each fac-
tor) obtained from analyzing jointly the mRNA and
miRNA data consists of a group of heterogeneous mole-
cules (mRNAs, miRNAs). It is then the interaction among
molecules in the same group (i.e. factor) that defines an
emergent property. This was done on a dataset of 330
miRNAs and ~14,500 mRNAs that for our purposes were
merged (in the joint analysis) into a single table (contain-
ing all molecular data and as many clinical indications of
the tumor class as there are samples, twelve) [1]. Conver-
sely, traditional parallel analyses imply that the two
mRNA and miRNA data tables are studied separately, and
that annotation results are jointly discussed only after-
wards. Therefore, the association between miRNAs and
mRNAs relies solely on manual curation, while our
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(built in the factors) that can then be manually investi-
gated further to elucidate the exact nature of the associa-
tion. Results have shown that the designed approach is
more helpful than traditional approaches (that analyze dis-
tinctly the two tables of mRNA and miRNA data, or use
hierarchical clustering, correlation or tools specific for dif-
ferential analyses [2,8,9]) in identifying non-trivial biologi-
cal properties [1]. In fact, in contrast to traditional
approaches, we were able to discover the relevance of two
miRNA clusters (miR-17-92 and miR-106-363), which
appear to be important for the diagnosis of glioblastoma
versus gliosarcomas. A cluster is a group of co-localized
miRNAs, in this particular case one maps onto Chromo-
some X (miR-17-92) and one maps onto Chromosome 13
(miR-106-363).
Briefly, these polycistronic miRNA genes are involved
in cell proliferation, apoptosis suppression, tumor angio-
genesis [10] and T cell leukemia [11]. Although lying on
different areas of the genome, the two clusters are clo-
sely related because each miRNA on one cluster has at
least one homologue in the other cluster except for
miR-17-3p and miR-363 that do not share homology
with the other miRNAs. Finally, we have observed that
the list of predicted targets (using the Targetscan soft-
ware, [12]) is identical for all miRNAs.
2 Independent Validation of Findings
The present article relates and discusses the coherence
of the findings in two independent publications, the one
described above and reported in [1] and the indepen-
dent validation published in [13], where the authors
identify an innovative miRNAs u r v i v a ls i g n a t u r ef o r
Glioblastomas, based on a classical statistical approach
(survival analysis), on a much larger set of data (222
glioblastomas from The Cancer Genome Atlas dataset).
In more recent years miRNAs have appeared to be
extremely meaningful in the evolution of tumors [14]
and the results presented in [13] confirm this trend.
The signature identified in [13] is composed of ten miR-
NAs, three of which appear to be protective (i.e. allowing
longer survival when overexpressed), and seven are risky
(viceversa).
In summary, the two papers we compare are related
to: (i) identification of a miRNA survival signature per-
formed with survival Cox statistics on miRNA glioblas-
toma data [13]; (ii) identification of emergent properties
performed with factor analysis on four types of mRNA
and miRNA glioma data processed in the same table [1].
The second one represents a very general question
(identification of distinctive molecular characteristics of
different types of tumors), and yet it is able to identify,
as emergent property, the protective action of the same
miRNAs highlighted in the survival analysis.
Therefore the same molecules could be isolated with
both methods, and complementary advantages. The first
approach [13] has a clear clinical focus with results rele-
vant in diagnosis and prognosis, additionally, to provide
sufficient statistical power to the test, this work is based
on a large dataset. The second approach [1] was not
guided by a specific medical nor biological question,
indeed it represented an extended analysis on a much
smaller dataset, originally collected to explore the con-
nection between miRNAs and their targets in gliomas.
Nevertheless, it was able to extract clinically relevant
information. In fact, the protective markers identified in
[13] (namely hsa-miR-20a; hsa-miR-106a; hsa-miR-17-
5p) all lie on the clusters miR-17-92 and miR-106-363
identified by our analysis in [1]. Figure 1 depicts the
relationship between the two sets of results.
3 Discussion
In our previous paper [1] we reported that the involve-
ment of cluster miR-17-92 is related to solid tumor
angiogenesis, and since the associated factor is related
to the discrimination of gliosarcomas from other brain
tumors, we concluded that cluster miR-17-92 (and its
homologous-rich companion, cluster miR-106-363)
could be involved in the development of the sarcoma-
tous element. In fact, despite the poor prognosis, glio-
sarcomas generally allow a longer survival time than
glioblastomas [15] due to the protective sarcomatous
component of the tumor [16,17]. Overall, since the sar-
comatous element is regulated by miR-17-92 and miR-
106-363, these clusters can be associated to better survi-
val: this is now independently confirmed by [13].
Additionally, we can speculate further on the role of
mir-193a. This is identified in [13] as a risk factor, mean-
ing that its overexpression leads to shorter survival. In our
analysis [1] mir-193a appears to be negatively associated
to the factor that characterizes less aggressive tumors.
This mathematical feature (the negative sign of mir-193a
in the factors Loadings matrix, [7]) translates into biologi-
cal terms as less aggressive tumors being associated to
diminshed activity of mir-193a, from which, we can indir-
ectly infer that its over activity is, if anything, a risk factor.
Globally, the coherence of the results obtained in [1]
and in [13] highlighted in the present article, namely the
relevance of the polycistronic miR-17-92 and miR-106-
363 miRNA genes, is promising in two main respects.
First, the results from both papers [1,13] confirm the
importance of the polycistronic clusters in clinical practice,
for their ability to predict better prognosis, and conse-
quently to better tailor patients’ therapy. Second, it offers a
useful analysis tool in the clinical bioinformatics research
area. In fact, the dropping costs of high-throughput tech-
nologies allow many laboratories to have access to omic
transcriptional and post-transcriptional screens, either
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O n ee x a m p l ef o ra l li st h ew o r kb e i n gd o n eb ym u l t i p l e
labs on the NCI-60 cancer cell lines (http://discover.nci.
nih.gov/cellminer/home.do) for which different labora-
tories have produced different omic data layers (mRNA
and miRNA in [18] or mRNA and proteins in [19]). In this
scenario it becomes natural to consider the possibility to
merge (or generate missing layers and then merge) differ-
ent data layers (mRNAs, miRNAs, proteins, etc.) to obtain
more information than the analysis of one single layer can
give. The type of information obtained can be used to dig
into the molecular features of different subtypes of cancers
(see classical approaches like [20-22]), or to associate
molecular with phenotypic and clinical features [1,23].
Our joint approach is tailored for the above depicted sce-
nario, where different types of data are merged. In particu-
lar, our approach is useful to extract information beyond
the results that can be obtained by expression profile cor-
relation and by clustering or SAM analysis applied to each
omic layer independently.
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